Scilex Holding Company Common Stock
Symbol: SCLX (NASDAQ)
Company Description:
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
- Today's Open: $0
- Today's High: $0
- Today's Low: $0
- Today's Volume: 0
- Yesterday Close: $13.17
- Yesterday High: $13.805
- Yesterday Low: $13.03
- Yesterday Volume: 71.63K
- Last Min Volume: 0
- Last Min High: $0
- Last Min Low: $0
- Last Min VWAP: $0
- Name: Scilex Holding Company Common Stock
- Website: https://www.scilexholding.com
- Listed Date: 2022-11-11
- Location: PALO ALTO, CA
- Market Status: Active
- CIK Number: 0001820190
- SIC Code: 2836
- SIC description: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
- Market Cap: $101.84M
- Round Lot: 100
- Outstanding Shares: 7.41M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-10-14 | D | View |
2025-10-14 | SCHEDULE 13D/A | View |
2025-10-09 | 4 | View |
2025-10-09 | 4 | View |
2025-10-09 | 4 | View |
2025-10-09 | 4 | View |
2025-10-09 | 4 | View |
2025-10-07 | 424B3 | View |
2025-10-07 | 424B3 | View |
2025-10-07 | 424B3 | View |
2025-10-07 | 8-K | View |
2025-10-02 | SCHEDULE 13D | View |
2025-10-02 | 424B3 | View |
2025-10-02 | 424B3 | View |
2025-10-02 | 424B3 | View |
2025-10-01 | 8-K | View |
2025-09-29 | 424B3 | View |
2025-09-29 | 424B3 | View |
2025-09-29 | 424B3 | View |
2025-09-26 | 8-K | View |